about
Metastasis suppressor genesThe role of p53 in cell-cycle control and apoptosis: implications for cancerLasers in the management of upper aerodigestive malignancies.Image correlation in oncology.In vitro assays of chemotherapeutic sensitivity.The phenomenon of pleiotropic drug resistance.Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.Retinoid chemoprevention of upper aerodigestive tract carcinogenesis.Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy.Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!The biochemical nature of the cell cycle.Immunotoxin therapy of malignancy.The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.The use of intraoperative ultrasound during cancer surgery.Quality of life measurements in cancer treatment.Meta-analysis of randomized control trials applied to cancer therapy.Quo vadis meta-analysis? A potentially dangerous tool if used without adequate rules.Perfluorochemical emulsions: oxygen breathing in radiation sensitization and chemotherapy modulation.Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression.The multidrug resistance phenotype in human cancer.Adjuvant therapy for node-negative breast cancer: a cautious interpretation.Molecular and cellular mechanisms of angiogenesis.Colony-stimulating factors: clinical status.Role of imaging in the evaluation of pelvic cancer.High-dose chemotherapy and autologous bone marrow support for breast cancer.Three-dimensional conformal treatment: a new frontier in radiation therapy.Treatment of patients with cancer of unknown primary site.Chemotherapy and the management of locally advanced squamous cell carcinoma of the head and neck: role in larynx preservation.Progress in decreasing cigarette smoking.Is a mechanism such as the NCI's Clinical Alert ever an appropriate alternative to journal peer review?Clinical Alert: a poor idea prematurely used.Potential innovations in scheduling of cancer chemotherapy.Molecular genetics of lymphoproliferative processes.5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.Bone marrow transplantation for the treatment of chronic myelogenous leukemia.Adjuvant therapy for node-negative breast cancer: a proactive view.Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
P1433
Q28290453-19AAA2B4-2889-443F-AF74-913B71DA52FCQ28611437-9B6C812D-A51E-4B28-980E-8FC9EB6F9501Q33254043-CF5AA6CE-4C50-4CFD-A9D4-0796D35DDE92Q33985591-4C8DF163-6650-44DE-856C-DE6B449A9E24Q34195024-FEC71735-BCAB-444C-9C88-CCA0C3493B8AQ34661400-2B7A2B1F-705F-4AB0-970D-5543FA35997CQ35228029-2C3E56B1-0629-43E3-B0AA-9845D70C98E0Q35228032-230C2532-B94B-49A6-9655-55188B14CCEEQ35317690-792AF35F-A794-4DE0-97DA-5016F16F4386Q35875037-BC6E1784-C7AF-4D05-B6A9-6CDD350B222CQ35875040-318DE9E3-99DE-4B21-9DB7-CB5E7C3C3457Q35875050-9A22F1FE-81B6-468E-B168-7C65D13C0CF7Q36096431-1D833C56-4478-422C-B9BE-D96F84882880Q36096443-C97D9363-32A8-4DD8-A18A-9B766BE058A3Q36096446-178ADFED-D9F4-47A7-A445-89BD03B168BFQ36096489-78BB754B-DB11-40B0-AE81-7AB89E1CEA8BQ36096513-B6F32AB9-8DDE-4052-9CE2-D332607D7D05Q36096520-2260ADF5-6AB8-4966-8145-CCF4D9405B77Q36096525-F29C32F8-8859-44EB-98B2-E187BBF15698Q36411733-9DDD203A-EE81-48A8-AC0D-D3CFB2973B04Q36510940-EB0C8DD6-541F-4C19-AF45-BFFB433CC046Q36566736-44EABB23-4E71-4847-8C30-249215160097Q36566747-B6E797CE-49FB-4D0B-8525-6E99EF0865B4Q36672949-27C3BA43-DEE5-4CCA-9125-5FA940DA934AQ37240594-369C27DC-E4DB-44BC-8AF7-076E5D062C45Q37240602-19E8E610-7C4D-4D25-8CC0-BED0CA578269Q37240607-9A245DB6-2C1E-4448-958E-78D1FE6E8892Q37240611-0FD57F0E-0BA9-43E2-B840-58351FEFA853Q37240621-CD4FB5CE-976E-4247-BEEE-3CE837CC6BACQ37240628-0A5E6E0A-55AA-4FB8-8F40-2CA794460FA8Q37240631-9B01951A-69B2-4909-8ADE-4C91A1472B56Q37240641-DFEBC7B3-60BA-4CE0-9D24-6ABE709782C9Q37240647-2599EA62-2B76-43DE-A97A-5139A5EC9469Q37913751-26DFC8CA-FC7D-40C5-82BD-AC43D589E0E9Q37913753-A1DC6CF0-A114-4D76-8DAE-08388778A2CAQ37913756-3409815D-194B-424A-B125-D3D87006416CQ37913757-2F782FAD-BD25-4976-A7F4-4123FAF75DEAQ37913759-497BBCE9-B6B6-4148-B623-05FA3E66B629Q37913762-89121860-583C-4DCA-BDD3-CCD9641A21A1Q37913766-4B145ED4-8315-4E72-825A-BB568D0E6E3B
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Lippincott Williams & Wilkins
@nl
wissenschaftliche Fachzeitschrift
@de
name
Important advances in oncology
@ast
Important advances in oncology
@en
Important advances in oncology
@es
Important advances in oncology
@it
Important advances in oncology
@nl
type
label
Important advances in oncology
@ast
Important advances in oncology
@en
Important advances in oncology
@es
Important advances in oncology
@it
Important advances in oncology
@nl
altLabel
Important Adv Oncol
@en
Important Adv. Oncol.
@en
prefLabel
Important advances in oncology
@ast
Important advances in oncology
@en
Important advances in oncology
@es
Important advances in oncology
@it
Important advances in oncology
@nl
P1055
P1156
P1476
Important advances in oncology
@en